ACRO Biomedical Co., Ltd.

As of June 30, 2026, ACRO Biomedical Co., Ltd. carries a market capitalization of 12.07B, placing it among publicly traded companies globally. Its enterprise value stands at 11.19B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, ACRO Biomedical Co., Ltd. has 71.22M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, ACRO Biomedical Co., Ltd. maintains a current ratio of 62.28, meaning it holds 62.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, ACRO Biomedical Co., Ltd.'s stock has gained approximately 165.96% over the past 52 weeks. The 50-day moving average sits at 192.62, while the 200-day moving average is 122.64.

As of June 30, 2026, ACRO Biomedical Co., Ltd. holds 916.68M in cash and equivalents against 33.63M in total debt, resulting in a net debt position of -449.48M. Total book value stands at 1.07B, with working capital of 943.36M providing operational flexibility.

ACRO Biomedical Co., Ltd.'s most recent stock split took place on November 24, 2025 with a 94:95 split ratio.